Bow EJ, Loewen R, Cheang MS et al.. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254–2261.

• PubMed
BowEJLoewenRCheangMS. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254–2261.)| false
• Search Google Scholar
• Export Citation

Pfaller MA, Messer SA, Houston A et al.. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998;31:289–296.

• PubMed
PfallerMAMesserSAHoustonA. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998;31:289–296. )| false
• Search Google Scholar
• Export Citation

Pfaller MA, Jones RN, Messer SA et al.. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998;31:327–332.

• PubMed
PfallerMAJonesRNMesserSA. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998;31:327–332. )| false
• Search Google Scholar
• Export Citation

Pfaller MA, Jones RN, Messer SA et al.. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998;30:121–129.

• PubMed
PfallerMAJonesRNMesserSA. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998;30:121–129. )| false
• Search Google Scholar
• Export Citation

Edwards JE Jr, Bodey GP, Bowden RA et al.. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [see comments]. Clin Infect Dis 1997;25:43–59.

• PubMed
EdwardsJE JrBodeyGPBowdenRA. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [see comments]. Clin Infect Dis 1997;25:43–59. )| false
• Search Google Scholar
• Export Citation

Viscoli C, Girmenia C, Marinus A et al.. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071–1079.

• PubMed
ViscoliCGirmeniaCMarinusA. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071–1079. )| false
• Search Google Scholar
• Export Citation

Anaissie EJ, Kontoyiannis DP, O'Brien S et al.. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559–566.

• PubMed
AnaissieEJKontoyiannisDPO'BrienS. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559–566. )| false
• Search Google Scholar
• Export Citation

Thaler M, Pastakia B, Shawker TH et al.. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988;108:88–100.

• PubMed
ThalerMPastakiaBShawkerTH. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988;108:88–100. )| false
• Search Google Scholar
• Export Citation

Karthaus M, Huebner G, Elser C et al.. Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation. Ann Hematol 1998;77:41-45.

• PubMed
KarthausMHuebnerGElserC. Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation. Ann Hematol 1998;77:41-45. )| false
• Search Google Scholar
• Export Citation

Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis—a contraindication to marrow transplantation? Blood 1994;84:2811–14.

• PubMed
BjerkeJWMeyersJDBowdenRA. Hepatosplenic candidiasis—a contraindication to marrow transplantation? Blood 1994;84:2811–14. )| false
• Search Google Scholar
• Export Citation

Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995;76:2357–2362.

• PubMed
WalshTJWhitcombPORevankarSGPizzoPA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995;76:2357–2362. )| false
• Search Google Scholar
• Export Citation

Pappas PG, Rex JH, Sobel JD et al.. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161–89 (Epub 2003 Dec 19).

• PubMed
PappasPGRexJHSobelJD. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161–89 (Epub 2003 Dec 19). )| false
• Search Google Scholar
• Export Citation

Rex JH, Bennett JE, Sugar AM et al.. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute (see comments). N Engl J Med 1994;331:1325–1330.

• PubMed
RexJHBennettJESugarAM. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute (see comments). N Engl J Med 1994;331:1325–1330. )| false
• Search Google Scholar
• Export Citation

Rex JH, Pappas PG, Karchmer AW et al.. A randomized and blinded multicenter trial of high-dose fluconazole (F) + placebo (P) vs. F + amphotericin B (A) as treatment of candidemia in non-neutropenic patients. In: Chicago, IL: 41st Annual ICAAC; December 16–19, 2001.

• PubMed
RexJHPappasPGKarchmerAW. A randomized and blinded multicenter trial of high-dose fluconazole (F) + placebo (P) vs. F + amphotericin B (A) as treatment of candidemia in non-neutropenic patients. In: Chicago, IL: 41st Annual ICAAC; December 16–19, 2001. )| false
• Search Google Scholar
• Export Citation

Rex JH, Pappas PG, Karchmer AW et al.. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221–1228.

• PubMed
RexJHPappasPGKarchmerAW. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221–1228. )| false
• Search Google Scholar
• Export Citation

Anaissie EJ, Vartivarian SE, Abi-Said D et al.. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170–176.

• PubMed
AnaissieEJVartivarianSEAbi-SaidD. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170–176. )| false
• Search Google Scholar
• Export Citation

Anaissie EJ, Darouiche RO, Abi-Said D et al.. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964–972.

• PubMed
AnaissieEJDarouicheROAbi-SaidD. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964–972. )| false
• Search Google Scholar
• Export Citation

Mora-Duarte J, Betts R, Rotstein C et al.. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020–2029.

• PubMed
Mora-DuarteJBettsRRotsteinC. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020–2029. )| false
• Search Google Scholar
• Export Citation

Walsh TJ, Seibel NL, Arndt C et al.. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18:702–708.

• PubMed
WalshTJSeibelNLArndtC. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18:702–708. )| false
• Search Google Scholar
• Export Citation

Walsh TJ, Whitcomb P, Piscitelli S et al.. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944–1948.

• PubMed
WalshTJWhitcombPPiscitelliS. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944–1948. )| false
• Search Google Scholar
• Export Citation

Walsh TJ, Hiemenz JW, Seibel NL et al.. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383–1396.

• PubMed
WalshTJHiemenzJWSeibelNL. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383–1396. )| false
• Search Google Scholar
• Export Citation

Rex JH, Bennett JE, Sugar AM et al.. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995;21:994–996.

• PubMed
RexJHBennettJESugarAM. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995;21:994–996. )| false
• Search Google Scholar
• Export Citation

Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 1996;22(suppl 2):S73–S88.

• PubMed
ColeGTHalawaAAAnaissieEJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 1996;22(suppl 2):S73–S88. )| false
• Search Google Scholar
• Export Citation

Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001;33:1959–1967.

• PubMed
NucciMAnaissieE. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001;33:1959–1967. )| false
• Search Google Scholar
• Export Citation

Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002;34:591–599.

• PubMed
NucciMAnaissieE. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002;34:591–599. )| false
• Search Google Scholar
• Export Citation

Gerson SL, Talbot GH, Hurwitz S et al.. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345–351.

• PubMed
GersonSLTalbotGHHurwitzS. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345–351. )| false
• Search Google Scholar
• Export Citation

Marr KA, Carter RA, Crippa F et al.. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909–917.

• PubMed
MarrKACarterRACrippaF. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909–917. )| false
• Search Google Scholar
• Export Citation

Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation (see comments). J Infect Dis 1997;175:1459–1466.

• PubMed
WaldALeisenringWvan BurikJABowdenRA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation (see comments). J Infect Dis 1997;175:1459–1466. )| false
• Search Google Scholar
• Export Citation

Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319–1324.

• PubMed
BaddleyJWStroudTPSalzmanDPappasPG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319–1324. )| false
• Search Google Scholar
• Export Citation

Grow WB, Moreb JS, Roque D et al.. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002;29:15–19.

• PubMed
GrowWBMorebJSRoqueD. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002;29:15–19. )| false
• Search Google Scholar
• Export Citation

Jantunen E, Ruutu P, Niskanen L et al.. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801–808.

• PubMed
JantunenERuutuPNiskanenL. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801–808. )| false
• Search Google Scholar
• Export Citation

McWhinney PH, Kibbler CC, Hamon MD et al.. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397–404.

• PubMed
McWhinneyPHKibblerCCHamonMD. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397–404. )| false
• Search Google Scholar
• Export Citation

Yuen KY, Woo PC, Ip MS et al.. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997;25:37–42.

• PubMed
YuenKYWooPCIpMS. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997;25:37–42. )| false
• Search Google Scholar
• Export Citation

Marr KA, Carter RA, Boeckh M et al.. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358–4366.

• PubMed
MarrKACarterRABoeckhM. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358–4366. )| false
• Search Google Scholar
• Export Citation

Anaissie EJ, Stratton SL, Dignani MC et al.. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002;34:780–789.

• PubMed
AnaissieEJStrattonSLDignaniMC. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002;34:780–789. )| false
• Search Google Scholar
• Export Citation

Yu VL, Muder RR, Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med 1986;81:249–254.

• PubMed
YuVLMuderRRPoorsattarA. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med 1986;81:249–254. )| false
• Search Google Scholar
• Export Citation

Caillot D, Casasnovas O, Bernard A et al.. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139–147.

• PubMed
CaillotDCasasnovasOBernardA. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139–147. )| false
• Search Google Scholar
• Export Citation

Kuhlman JE, Fishman EK, Burch PA et al.. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest 1987;92:95–99.

• PubMed
KuhlmanJEFishmanEKBurchPA. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest 1987;92:95–99. )| false
• Search Google Scholar
• Export Citation

Bretagne S, Costa JM, Bart-Delabesse E et al.. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998;26:1407–1412.

• PubMed
BretagneSCostaJMBart-DelabesseE. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998;26:1407–1412. )| false
• Search Google Scholar
• Export Citation

Maertens J, Verhaegen J, Lagrou K et al.. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97:1604–1610.

• PubMed
MaertensJVerhaegenJLagrouK. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97:1604–1610. )| false
• Search Google Scholar
• Export Citation

Maertens J, Van Eldere J, Verhaegen J et al.. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:1297–1306.

• PubMed
MaertensJVan EldereJVerhaegenJ. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:1297–1306. )| false
• Search Google Scholar
• Export Citation

Herbrecht R, Letscher-Bru V, Oprea C et al.. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898–1906.

• PubMed
HerbrechtRLetscher-BruVOpreaC. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898–1906. )| false
• Search Google Scholar
• Export Citation

INFO-FDA. FDA clears rapid test for Aspergillus infection. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00907.html. Accessed July 2004.

• PubMed
INFO-FDA. FDA clears rapid test for Aspergillus infection. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00907.html. Accessed July 2004. )| false
• Search Google Scholar
• Export Citation

Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003;349:2366–2367.

• PubMed
SulahianATouratierSRibaudP. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003;349:2366–2367. )| false
• Search Google Scholar
• Export Citation

Ascioglu S, Rex JH, de Pauw B et al.. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7–14.

• PubMed
AsciogluSRexJHde PauwB. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7–14. )| false
• Search Google Scholar
• Export Citation

Walsh TJ, Finberg RW, Arndt C et al.. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764–771

• PubMed
WalshTJFinbergRWArndtC. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764–771 )| false
• Search Google Scholar
• Export Citation

Bowden R, Chandrasekar P, White MH et al.. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359–366 (Epub 2002 Jul 25).

• PubMed
BowdenRChandrasekarPWhiteMH. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359–366 (Epub 2002 Jul 25). )| false
• Search Google Scholar
• Export Citation

Chopra R. AmBisome in the treatment of fungal infections: the UK experience. J Antimicrob Chemother 2002;49(suppl 1):43–47.

• PubMed
ChopraR. AmBisome in the treatment of fungal infections: the UK experience. J Antimicrob Chemother 2002;49(suppl 1):43–47. )| false
• Search Google Scholar
• Export Citation

Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754–760.

• PubMed
MillsWChopraRLinchDCGoldstoneAH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754–760. )| false
• Search Google Scholar
• Export Citation

Herbrecht R, Denning DW, Patterson TF et al.. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.

• PubMed
HerbrechtRDenningDWPattersonTF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415. )| false
• Search Google Scholar
• Export Citation

Denning DW, Ribaud P, Milpied N et al.. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563–571.

• PubMed
DenningDWRibaudPMilpiedN. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563–571. )| false
• Search Google Scholar
• Export Citation

Troke PF, Schwartz S, Ruhnke M et al.. Voriconazole (VCR) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003.

• PubMed
TrokePFSchwartzSRuhnkeM. Voriconazole (VCR) therapy (Rx) in 86 patients (pts) with CNS aspergillosis (CNSA): a retrospective analysis. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003. )| false
• Search Google Scholar
• Export Citation

Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608–615.

• PubMed
DenningDW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608–615. )| false
• Search Google Scholar
• Export Citation

Walsh TJ, Lutsar I, Driscoll T et al.. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240–248.

• PubMed
WalshTJLutsarIDriscollT. Voriconazole in the treatment of aspergillosis, scedosporiosis, and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240–248. )| false
• Search Google Scholar
• Export Citation

Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP et al.. Invasive aspergillosis (IA) caused by Aspergillus terreus: multicenter retrospective analysis of 87 cases. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003.

• PubMed
SteinbachWJBenjaminDK JrKontoyiannisDP. Invasive aspergillosis (IA) caused by Aspergillus terreus: multicenter retrospective analysis of 87 cases. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003. )| false
• Search Google Scholar
• Export Citation

Kartsonis N, Saah A, Lipka J et al.. Salvage therapy (Rx) with Caspofungin (CAS) for invasive aspergillosis (IA): results from the CAS compassionate use (CU) study. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003.

• PubMed
KartsonisNSaahALipkaJ. Salvage therapy (Rx) with Caspofungin (CAS) for invasive aspergillosis (IA): results from the CAS compassionate use (CU) study. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003. )| false
• Search Google Scholar
• Export Citation

Caspofungin (Cancidas) for aspergillosis. Med Lett Drugs Ther 2001;43:58–59.

• PubMed
Caspofungin (Cancidas) for aspergillosis. Med Lett Drugs Ther 2001;43:58–59. )| false
• Search Google Scholar
• Export Citation

Gea-Banacloche JC, Peter J, Bishop M et al.. Successful treatment of invasive aspergillosis with the combination of voriconazole and caspofungin: correlation with in vitro interactions. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003.

• PubMed
Gea-BanaclocheJCPeterJBishopM. Successful treatment of invasive aspergillosis with the combination of voriconazole and caspofungin: correlation with in vitro interactions. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003. )| false
• Search Google Scholar
• Export Citation

Kontoyiannis DP, Hachem R, Lewis RE et al.. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98:292–299.

• PubMed
KontoyiannisDPHachemRLewisRE. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98:292–299. )| false
• Search Google Scholar
• Export Citation

Aliff TB, Maslak PG, Jurcic JG et al.. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003;97:1025–1032.

• PubMed
AliffTBMaslakPGJurcicJG. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003;97:1025–1032. )| false
• Search Google Scholar
• Export Citation

Offner F, Cordonnier C, Ljungman P et al.. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:1098–1103.

• PubMed
OffnerFCordonnierCLjungmanP. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:1098–1103. )| false
• Search Google Scholar
• Export Citation

Goodman JL, Winston DJ, Greenfield RA et al.. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation (see comments). N Engl J Med 1992;326:845–851.

• PubMed
GoodmanJLWinstonDJGreenfieldRA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation (see comments). N Engl J Med 1992;326:845–851. )| false
• Search Google Scholar
• Export Citation

Slavin MA, Osborne B, Adams R et al.. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545–1552.

• PubMed
SlavinMAOsborneBAdamsR. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545–1552. )| false
• Search Google Scholar
• Export Citation

Marr KA, Seidel K, Slavin MA et al.. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055–2061.

• PubMed
MarrKASeidelKSlavinMA. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055–2061. )| false
• Search Google Scholar
• Export Citation

Bow EJ, Laverdiere M, Lussier N et al.. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230–3246.

• PubMed
BowEJLaverdiereMLussierN. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230–3246. )| false
• Search Google Scholar
• Export Citation

Viscoli C, Paesmans M, Sanz M et al.. Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis 2001;32:1532–1537.

• PubMed
ViscoliCPaesmansMSanzM. Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis 2001;32:1532–1537. )| false
• Search Google Scholar
• Export Citation

Rotstein C, Bow EJ, Laverdiere M et al.. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331–340.

• PubMed
RotsteinCBowEJLaverdiereM. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331–340. )| false
• Search Google Scholar
• Export Citation

Winston DJ, Chandrasekar PH, Lazarus HM et al.. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial (see comments). Ann Intern Med 1993;118:495–503.

• PubMed
WinstonDJChandrasekarPHLazarusHM. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial (see comments). Ann Intern Med 1993;118:495–503. )| false
• Search Google Scholar
• Export Citation

Kern W, Behre G, Rudolf T et al.. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998;83:291–301.

• PubMed
KernWBehreGRudolfT. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998;83:291–301. )| false
• Search Google Scholar
• Export Citation

Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309–316.

• PubMed
MarrKASeidelKWhiteTCBowdenRA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309–316. )| false
• Search Google Scholar
• Export Citation

Zhou H, Goldman M, Wu J et al.. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 1998;38:593–602.

• PubMed
ZhouHGoldmanMWuJ. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 1998;38:593–602. )| false
• Search Google Scholar
• Export Citation

Menichetti F, Del Favero A, Martino P et al.. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999;28:250–255.

• PubMed
MenichettiFDel FaveroAMartinoP. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999;28:250–255. )| false
• Search Google Scholar
• Export Citation

Morgenstern GR, Prentice AG, Prentice HG et al.. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999;105:901–911.

• PubMed
MorgensternGRPrenticeAGPrenticeHG. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999;105:901–911. )| false
• Search Google Scholar
• Export Citation

Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999;24:1089–1093.

• PubMed
FootABVeysPAGibsonBE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999;24:1089–1093. )| false
• Search Google Scholar
• Export Citation

Harousseau JL, Dekker AW, Stamatoullas-Bastard A et al.. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44:1887–1893.

• PubMed
HarousseauJLDekkerAWStamatoullas-BastardA. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44:1887–1893. )| false
• Search Google Scholar
• Export Citation

Crippa F, Corey L, Leisenring W et al.. Administration of Itraconazole for antifungal prophylaxis in stem cell transplant recipients: levels and drug interactions. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 2000.

• PubMed
CrippaFCoreyLLeisenringW. Administration of Itraconazole for antifungal prophylaxis in stem cell transplant recipients: levels and drug interactions. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 2000. )| false
• Search Google Scholar
• Export Citation

Glasmacher A, Molitor E, Hahn C et al.. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998;12:1338–1343.

• PubMed
GlasmacherAMolitorEHahnC. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998;12:1338–1343. )| false
• Search Google Scholar
• Export Citation

Winston DJ, Maziarz RT, Chandrasekar PH et al.. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138: 705–713.

• PubMed
WinstonDJMaziarzRTChandrasekarPH. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138: 705–713. )| false
• Search Google Scholar
• Export Citation

Marr KA, Crippa F, Leisenring W et al.. Itraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 2003;2:2.

• PubMed
MarrKACrippaFLeisenringW. Itraconazole versus fuconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 2003;2:2. )| false
• Search Google Scholar
• Export Citation

Marr KA, Leisenring W, Crippa F et al.. Cyclophosphamide metabolism is impacted by azole antifungals. Blood 2003;22:22.

• PubMed
MarrKALeisenringWCrippaF. Cyclophosphamide metabolism is impacted by azole antifungals. Blood 2003;22:22. )| false
• Search Google Scholar
• Export Citation

Bodey GP, Anaissie EJ, Elting LS et al.. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099–2106.

• PubMed
BodeyGPAnaissieEJEltingLS. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099–2106. )| false
• Search Google Scholar
• Export Citation

Mattiuzzi GN, Kantarjian H, Faderl S et al.. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004;100:581–589.

• PubMed
MattiuzziGNKantarjianHFaderlS. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004;100:581–589. )| false
• Search Google Scholar
• Export Citation

van Burik J, Ratanatharathorn V, Lipton J et al.. Randomized, double-blind trial of Micafungin (MI) versus fluconazole (FL for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG protocol 46. In: Annual ICAAC. Chicago, IL; 2002.

• PubMed
van BurikJRatanatharathornVLiptonJ. Randomized, double-blind trial of Micafungin (MI) versus fluconazole (FL for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG protocol 46. In: Annual ICAAC. Chicago, IL; 2002. )| false
• Search Google Scholar
• Export Citation

Sullivan KM, Dykewicz CA, Longworth DL et al.. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology (Am Soc Hematol Educ Program) 2001:392–421.

• PubMed
SullivanKMDykewiczCALongworthDL. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology (Am Soc Hematol Educ Program) 2001:392–421. )| false
• Search Google Scholar
• Export Citation

Hahn T, Cummings KM, Michalek AM et al.. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol 2002;23:525–531.

• PubMed
HahnTCummingsKMMichalekAM. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol 2002;23:525–531. )| false
• Search Google Scholar
• Export Citation

Carter CD, Barr BA. Infection control issues in construction and renovation. Infect Control Hosp Epidemiol 1997;18:587–596.

• PubMed
CarterCDBarrBA. Infection control issues in construction and renovation. Infect Control Hosp Epidemiol 1997;18:587–596. )| false
• Search Google Scholar
• Export Citation

Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101–111.

• PubMed
PizzoPARobichaudKJGillFAWitebskyFG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101–111. )| false
• Search Google Scholar
• Export Citation

Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989;86:668–672.

• PubMed
Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989;86:668–672. )| false
• Search Google Scholar
• Export Citation

Cagnoni PJ, Walsh TJ, Prendergast MM et al.. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476–2483.

• PubMed
CagnoniPJWalshTJPrendergastMM. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476–2483. )| false
• Search Google Scholar
• Export Citation

Wingard JR, White MH, Anaissie E et al.. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155–1163.

• PubMed
WingardJRWhiteMHAnaissieE. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155–1163. )| false
• Search Google Scholar
• Export Citation

Boogaerts M, Winston DJ, Bow EJ et al.. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412–422.

• PubMed
BoogaertsMWinstonDJBowEJ. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412–422. )| false
• Search Google Scholar
• Export Citation

Winston DJ, Hathorn JW, Schuster MG et al.. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282–289.

• PubMed
WinstonDJHathornJWSchusterMG. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282–289. )| false
• Search Google Scholar
• Export Citation

Viscoli C, Castagnola E, Van Lint MT et al.. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996;32A:814–820.

• PubMed
ViscoliCCastagnolaEVan LintMT. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996;32A:814–820. )| false
• Search Google Scholar
• Export Citation

Walsh TJ, Pappas P, Winston DJ et al.. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225–234.

• PubMed
WalshTJPappasPWinstonDJ. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225–234. )| false
• Search Google Scholar
• Export Citation

Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950–952.

• PubMed
MartyFMCosimiLABadenLR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950–952. )| false
• Search Google Scholar
• Export Citation

Walsh T, Sable C, DePauw B et al.. A randomized, double-blind, multicenter trial of caspofungin (CS) v liposomal amphotericin B (LAMB) for empirical antifungal therapy (EAFrx) of persistently febrile neutropenic (PFN) patients (Pt). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003.

• PubMed
WalshTSableCDePauwB. A randomized, double-blind, multicenter trial of caspofungin (CS) v liposomal amphotericin B (LAMB) for empirical antifungal therapy (EAFrx) of persistently febrile neutropenic (PFN) patients (Pt). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003. )| false
• Search Google Scholar
• Export Citation

Godwin JE, Kopecky KJ, Head DR et al.. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998;91:3607–3615.

• PubMed
GodwinJEKopeckyKJHeadDR. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998;91:3607–3615. )| false
• Search Google Scholar
• Export Citation

Heil G, Hoelzer D, Sanz MA et al.. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997;90:4710–4718.

• PubMed
HeilGHoelzerDSanzMA. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997;90:4710–4718. )| false
• Search Google Scholar
• Export Citation

Rowe JM, Andersen JW, Mazza JJ et al.. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457–462.

• PubMed
RoweJMAndersenJWMazzaJJ. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457–462. )| false
• Search Google Scholar
• Export Citation

Ozer H, Armitage JO, Bennett CL et al.. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558–3585.

• PubMed
OzerHArmitageJOBennettCL. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558–3585. )| false
• Search Google Scholar
• Export Citation

Price TH, Bowden RA, Boeckh M et al.. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoeitic stem cell transplantation. Blood 2000;95:3302–3309.

• PubMed
PriceTHBowdenRABoeckhM. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoeitic stem cell transplantation. Blood 2000;95:3302–3309. )| false
• Search Google Scholar
• Export Citation

Nichols WG, Price T, Boeckh M. Cytomegalovirus infections in cancer patients receiving granulocyte transfusions. Blood 2002;99:3483–3484.

• PubMed
NicholsWGPriceTBoeckhM. Cytomegalovirus infections in cancer patients receiving granulocyte transfusions. Blood 2002;99:3483–3484. )| false
• Search Google Scholar
• Export Citation